Coherus_Logo_RGB_150.png
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:51 ET | Coherus BioSciences, Inc.
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T...
Coherus_Logo_RGB_150.png
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:02 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective...
Vaccinex logo
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
February 21, 2024 08:00 ET | Vaccinex, Inc.
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...
Coherus Logo - R@2x.png
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
November 03, 2023 08:30 ET | Coherus BioSciences, Inc.
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –...
Coherus Logo - R@2x.png
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27, 2023 09:10 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology...
Coherus Logo - R@2x.png
Coherus Completes Surface Oncology Acquisition
September 08, 2023 09:05 ET | Coherus BioSciences, Inc.
– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will...
Coherus Logo - R@2x.png
Coherus to Acquire Surface Oncology
June 16, 2023 07:01 ET | Coherus BioSciences, Inc.
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
December 20, 2021 08:00 ET | FibroGen, Inc.
Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones...
jounce.png
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting
June 22, 2020 09:00 ET | Jounce Therapeutics, Inc.
- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells - -...
jounce.png
Jounce Therapeutics to Present First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at the American Association for Cancer Research Virtual Annual Meeting
May 15, 2020 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...